Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Novavax Climbs as COVID-19 Vaccine Sales Finally Seen Coming Through

Published 03/01/2022, 11:24 PM
© Reuters
NVAX
-

By Dhirendra Tripathi

Investing.com – Novavax (NASDAQ:NVAX) stock surged 6.4% Tuesday after the company said its 2022 revenue will be around at least fourfold higher compared to a year ago, finally addressing concerns around the marketability of its COVID-19 vaccine.

The company has also developed an Omicron-specific vaccine and said it should begin manufacturing the doses by March-end.

The company is now guiding for annual revenue of $4 billion-$5 billion, up from $1.1 billion in 2021. A big chunk of the revenue will be through vaccine product sales, the company said. Novavax said it is keeping the second half of the year to pursue the full approval of its COVID-19 vaccine.

Held back due to manufacturing issues, Novavax was late by more than a year in bringing its COVID-19 vaccine to the market and filed with the FDA for emergency use authorization only late January.

The company had earlier forecast to deliver 2 billion COVID-19 shots around the world in 2022 but was silent Monday on the quantity it expects to hand over in the current quarter, Reuters said.  

According to the news agency, the company has completed delivery of around 9 million vaccine doses to Indonesia, 6 million to Australia, 2 million to South Korea, and expects to supply 69 million doses to Europe in the first half of this year.

Revenue in the fourth quarter fell 20% to $222 million owing to much higher grants received from the U.S. government and the Coalition for Epidemic Preparedness Innovations for its Covid vaccine in the same period last year. The Coalition is a global partnership to develop vaccines to stop future epidemics.

Royalty receipts rose in the fourth quarter as license partners in South Korea and Indonesia booked revenue from sales of the vaccine.

Adjusted net loss per share was $11.18 and worse than estimated, as expenses on research and development (R&D) and general and administrative (G&A) purposes more than doubled.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.